Vineti bags $34M to support CAR-T logistics

Canaan Partners and DFJ led the round with assists from Bill Maris’ Section 32, GE Ventures, Casdin Capital and LifeForce Capital. (pasja1000)

Vineti has raised $33.5 million to further its cloud-based cell therapy platform. The investment sets up the Kite Pharma-partnered firm to refine and expand software to automate and orchestrate the many steps involved in the production of cell and gene therapies. 

GE Ventures and Mayo Clinic founded Vineti, then known as Vitruvian Networks, two years ago to address the emerging logistical challenges associated with cell and gene therapy. The founders bet software could mitigate the challenge by orchestrating the interactions of the hospitals, blood banks, couriers and manufacturers involved in the production of personalized therapies. Within nine months of opening its doors, Vineti had a deal with Kite Pharma. 

Since then, the significance of the Kite deal and the broader cell therapy sector have increased as the FDA has approved the first CAR-T therapies and Celgene and Gilead have bought into the field.  


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Against that backdrop, Vineti has pulled in its second financing round in 10 months. The June series A gave Vineti almost $14 million to support the commercialization of its cloud-based logistics platform. This week’s series B gives Vineti a further $33.5 million to further the evolution and globalization of its offering. Further expansion in Europe and Asia-Pacific is next on Vineti’s roadmap.

RELATED: Vineti scores $13M+, launches cloud-based platform for cell therapies

Canaan and DFJ led the round with assists from Bill Maris’ Section 32, GE Ventures, Casdin Capital and LifeForce Capital. The mix of life science and tech investors reflects Vineti’s position at the intersection of the two industries. 

“We are leveraging the best of SIlicon Valley 'critical path' enterprise software to ensure that the right therapy gets to the right patient at the right time, safely and cost effectively,” Vineti CEO Amy DuRoss said in a statement.

Suggested Articles

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.

Inotrem and Roche’s diagnostics division have upgraded their years-long collaboration on a plasma test for septic shock, with a new worldwide deal.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.